Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): Study protocol for a randomised controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Harris, Patrick N A ^a   Peleg, Anton Y ^b   Iredell, Jon ^c   Ingram, Paul R ^d,e   Miyakis, Spiros ^f   Stewardson, Andrew J ^g   Rogers, Benjamin A ^h   McBryde, Emma S ⁱ   Roberts, Jason A ^j   Lipman, Jeff ^j   Athan, Eugene ^k   Paul, Sanjoy K ^l   Baker, Peter ^j   Harris Brown, Tiffany ^a   Paterson, David L ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f WOLLONGONG HOSPITAL   (Australia)

^g AUSTIN HEALTH   (Australia)

^h SOUTHERN HEALTH   (Australia)

ⁱ ROYAL MELBOURNE HOSPITAL   (Australia)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k DEAKIN UNIVERSITY   (Australia)

^l QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

more..

Author keywords

Beta lactam beta lactamase inhibitor; Carbapenem; Clinical trial; ESBL; Extended spectrum beta lactamase; Plasmid AmpC; Resistance; Therapy

Indexed keywords

CEFTRIAXONE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; THIENAMYCIN DERIVATIVE;

ADULT; ARTICLE; AUSTRALIA; BACTEREMIA; BLOODSTREAM INFECTION; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI INFECTION; HUMAN; KLEBSIELLA INFECTION; MORTALITY; MULTICENTER STUDY; NEW ZEALAND; RANDOMIZED CONTROLLED TRIAL; SINGAPORE; STUDY DESIGN; TREATMENT DURATION; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMPARATIVE STUDY; ESCHERICHIA COLI INFECTIONS; KLEBSIELLA INFECTIONS; PHASE 3 CLINICAL TRIAL; SAMPLE SIZE;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFTRIAXONE; CLINICAL PROTOCOLS; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; PENICILLANIC ACID; PIPERACILLIN; SAMPLE SIZE; THIENAMYCINS;

EID: 84938222503     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-014-0541-9     Document Type: Article

References (26)

1. Cohen J, Cristofaro P, Carlet J, Opal S. New method of classifying infections in critically ill patients. Crit Care Med. 2004;32(7):1510-26.
2. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159-66.
3. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86.
4. de Kraker MEA, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66(2):398-407.
5. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39(1):31-7.
6. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793-803.
7. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54(2):167-74.
8. Peralta G, Lamelo M, Alvarez-Garcia P, Velasco M, Delgado A, Horcajada JP, et al. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis. 2012;12:245.
9. McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131-3.
10. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53(1):60-7.
11. Boucher HW, Talbot GH, Benjamin Jr DK, Bradley J, Guidos RJ, Jones RN, et al. Infectious Diseases Society of A: 10×'20 progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685-94.
12. Drawz SM, Papp-Wallace KM, Bonomo RA. New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58(4):1835-46.
13. Tam VH, Ledesma KR, Chang KT, Wang TY, Quinn JP. Killing of Escherichia coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis. 2009;64(2):166-71.
14. Rice LB, Carias LL, Hujer AM, Bonafede M, Hutton R, Hoyen C, et al. High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2000;44(2):362-7.
15. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161-82.
16. Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect. 2011;62(4):280-91.
17. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682-707.
18. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria G. beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54(2):167-74.
19. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, Group C. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594-604.
20. Breakpoint tables for interpretation of MICs and zone diameters version 4.0. Available from: http://www.eucast.org . Accessed 6th December 2014.
21. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004;140(1):26-32.
22. Chow S-C, Hansheng W, Shao J. Sample size calculations in clinical research. 2nd ed. Boca Raton: Chapman Hall; 2007.
23. Harris PNA, Mo Y, Jureen R, Chew J, Ali J, Paterson DL, Tambyah PA. Meropenem and piperacillin-tazobactam have comparable outcomes in treatment of bloodstream infections caused by extended spectrum beta-lactamase producing E.coli and Klebsiellae. Abstract number 486, IDWeek. Philadelphia, PA: 8 to 12 October 2014. Available from: https://idsa.confex.com/idsa/2014/webprogram/Paper46679.html . Accessed 12th Jan 2015.
24. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance:mechanisms/EUCAST_detection_of_resistance:mechanisms_v1.0_20131211.pdf . Accessed 26th Jan 2015.
25. Paterson DL. Determining research priorities for clinician-initiated trials in infectious diseases. Med J Aust. 2013;198(5):270-2.
26. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med. 2013;368(4):299-302.